Optic neuritis
Optic neuritis describes any condition that causes inflammation of the optic nerve; it may be associated with demyelinating diseases, or infectious or inflammatory processes.[1]
Optic neuritis | |
---|---|
Characteristic disc edema and macular exudates seen in neuroretinitis | |
Specialty | Ophthalmology, optometry, neurology |
It is also known as optic papillitis (when the head of the optic nerve is involved), neuroretinitis (when there is a combined involvement of the optic disc and surrounding retina in the macular area) and retrobulbar neuritis (when the posterior part of the nerve is involved). Prelaminar optic neuritis describes involvement of the non-myelinated axons in the retina.[2] It is most often associated with multiple sclerosis, and it may lead to complete or partial loss of vision in one or both eyes. Other causes include:[3]
- Leber's hereditary optic neuropathy
- Parainfectious optic neuritis (associated with viral infections such as measles, mumps, chickenpox, whooping cough and glandular fever)
- Infectious optic neuritis (sinus related or associated with cat-scratch fever, tuberculosis, Lyme disease and cryptococcal meningitis in AIDS patients
- Autoimmune causes (sarcoidosis, systemic lupus erythematosus, polyarteritis nodosa, MOG antibody disease, granulomatosis with polyangiitis)
- Diabetes mellitus
- Low phosphorus levels
- Hyperkalaemia
Partial, transient vision loss (lasting less than one hour) can be an indication of early onset multiple sclerosis.[4]
Signs and symptoms
Major symptoms are sudden loss of vision (partial or complete), sudden blurred or "foggy" vision, and pain on movement of the affected eye.[5] Early symptoms that require investigation include symptoms from multiple sclerosis (twitching, lack of coordination, slurred speech, frequent episodes of partial vision loss or blurred vision), episodes of "disturbed/blackened" rather than blurry indicate moderate stage and require immediate medical attention to prevent further loss of vision. Other early symptoms are reduced night vision, photophobia and red eyes. Many patients with optic neuritis may lose some of their color vision in the affected eye (especially red), with colors appearing subtly washed out compared to the other eye. Patients may also experience difficulties judging movement in depth, which can be particular troublesome during driving or sport (Pulfrich effect). Likewise, transient worsening of vision with increase of body temperature (Uhthoff's phenomenon) and glare disability are a frequent complaint. However, several case studies in children have demonstrated the absence of pain in more than half of cases (approximately 60%) in their pediatric study population, with the most common symptom reported simply as "blurriness."[6][7] Other remarkable differences between the presentation of adult optic neuritis as compared to pediatric cases include more often unilateral optic neuritis in adults, while children much predominantly present with bilateral involvement.
On medical examination the head of the optic nerve can easily be visualized by a slit lamp with a high positive lens or by using direct ophthalmoscopy; however, frequently there is no abnormal appearance of the nerve head in optic neuritis (in cases of retrobulbar optic neuritis), though it may be swollen in some patients (anterior papillitis or more extensive optic neuritis). In many cases, only one eye is affected, and patients may not be aware of the loss of color vision until they are asked to close or cover the healthy eye.
Cause
The optic nerve comprises axons that emerge from the retina of the eye and carry visual information to the primary visual nuclei, most of which is relayed to the occipital cortex of the brain to be processed into vision. Inflammation of the optic nerve causes loss of vision, usually because of the swelling and destruction of the myelin sheath covering the optic nerve.
The most common cause is multiple sclerosis (MS) or ischemic optic neuropathy due to thrombosis or embolism of the vessel that supplies the optic nerve.[8][9] Up to 50% of patients with MS will develop an episode of optic neuritis, and 20-30% of the time optic neuritis is the presenting sign of MS. The presence of demyelinating white matter lesions on brain MRI at the time of presentation of optic neuritis is the strongest predictor for developing clinically definite MS. Almost half of the patients with optic neuritis have white matter lesions consistent with multiple sclerosis.
Some other common causes of optic neuritis include infection (e.g. a tooth abscess in the upper jaw, syphilis, Lyme disease, herpes zoster), autoimmune disorders (e.g. lupus, neurosarcoidosis, neuromyelitis optica), methanol poisoning, vitamin B12 deficiency, beriberi, dysautonomia (i.e. autonomic nervous system dysfunction), and diabetes, or an injury to the eye.[10] In neuromyelitis optica higher AQP4 autoantibody levels are associated with the occurrence of optic neuritis.[11]
Less common causes are: papilledema, brain tumor or abscess in the occipital region, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, sinus thrombosis, liver dysfunction, or late stage kidney disease.
Cause and Rank based on Deaths | Annual Num Cases TOTAL (US) (2011) | Annual Cases leading to Optic Neuritis | Percent | Prognosis and Treatment |
---|---|---|---|---|
Multiple sclerosis (Rank 33) | 400, 042 | 146,232 | 45% | Most common cause. Almost all patients will experience some form of vision dysfunction. Partial vision loss can occur through the duration of the disease; total vision loss occurs in severe cases and late stages. |
Blood clot (Rank 29) (Optic ONLY) | 17,000 | 16,777 | 5% | Reversible if early and before reduced blood flow causes permanent damage. |
Nerve pinch (0) | NOT REPORTED | - | 4% | Usually heals itself, treatment not needed. |
Injury to optic nerve (including poisoning, i.e. methanol) (0) | 23,827 | 20,121 | <1% | Depends on severity, usually treatable. |
Liver dysfunction (Rank 19); if untreated can lead to Failure (Rank 8) | 141,211 | 11,982 | 7% | Poor outcomes and progresses and can lead to total vision loss. |
Reduced kidney function (treatable with diet change) (Rank 67 – If untreated, can progress to late stage with much greater mortality rates) | 509,898 | 16,281 | 9% | Good outcomes if early, and can usually be treated with diet changes, progresses and can lead to total vision loss. |
Late stage kidney failure (Rank 7) | 33,212 | 1,112 | 2% | Poor outcomes – usually permanent nerve damage at this stage. |
Papilledema (brain tumor or abscess) (Rank 10) | 45,888 | 9,231 | 3% | Depends on severity. |
Meningitis (Rank 61) | 2,521 | 189 | <1% | Depends on severity. |
Other infections (not from abscess) | 5,561 | - | <1% | Good outcomes, treatable with antibiotics or other microbial drugs. |
Diabetes (early stage treatable, late Stage has worse prognosis) (Rank 6) | 49,562 | 21,112 | 15% | Type 1 carries poor prognosis, type 2 can be treated and vision returned. |
Unknown | - | - | 2% |
Demyelinating recurrent optic neuritis and non-demyelinating (CRION)
The repetition of an idiopathic optic neuritis is considered a distinct clinical condition, and when it shows demyelination, it has been found to be associated to anti-MOG and AQP4-negative neuromyelitis optica.[13]
When an inflammatory recurrent optic neuritis is not demyelinating, it is called chronic relapsing inflammatory optic neuropathy (CRION).[14]
When it is anti-MOG related, it is demyelinating and it is considered inside the anti-MOG associated inflammatory demyelinating diseases.
Some reports point to the possibility to establish a difference via optical coherence tomography.[15]
Treatment
In most MS-associated optic neuritis, visual function spontaneously improves over 2–3 months, and there is evidence that corticosteroid treatment does not affect the long term outcome. However, for optic neuritis that is not MS-associated (or atypical optic neuritis) the evidence is less clear and therefore the threshold for treatment with intravenous corticosteroids is lower.[16] Intravenous corticosteroids also reduce the risk of developing MS in the following two years in patients with MRI lesions; but this effect disappears by the third year of follow up.[17]
Paradoxically, oral administration of corticosteroids in this situation may lead to more recurrent attacks than in non-treated patients (though oral steroids are generally prescribed after the intravenous course, to wean the patient off the medication). This effect of corticosteroids seems to be limited to optic neuritis and has not been observed in other diseases treated with corticosteroids.[18]
A Cochrane systematic review studied the effect of corticosteroids for treating people with acute optic neuritis.[19] Specific corticosteroids studied included intravenous and oral methylprednisone, and oral prednisone. The authors conclude that current evidence does not show a benefit of either intravenous or oral corticosteroids for rate of recovery of vision (in terms of visual acuity, contrast sensitivity, or visual fields).[19] There are a number of reasons why this might be the case.[17][20]
Epidemiology
Optic neuritis typically affects young adults ranging from 18–45 years of age, with a mean age of 30–35 years. There is a strong female predominance. The annual incidence is approximately 5/100,000, with a prevalence estimated to be 115/100,000.[21]
Society and culture
In Charles Dickens' Bleak House, the main character, Esther Summerville, has a transient episode of visual loss, the symptoms of which are also seen in people who have optic neuritis.[22] Legal historian William Searle Holdsworth suggested that the events in Bleak House took place in 1827.
In an episode of Dr. Quinn, Medicine Woman ("Season of Miracles", season five), Reverend Timothy Johnson is struck blind by optic neuritis on Christmas Day 1872. He remains blind for the duration of the series.
See also
References
- Petzold, A; Fraser, CL; Abegg, M; et al. (September 2022). Diagnosis and classification of optic neuritis. Lancet Neurology. doi:10.1016/S1474-4422(22)00200-9
- Petzold, Axel; Fraser, Clare L; Abegg, Mathias; Alroughani, Raed; Alshowaeir, Daniah; Alvarenga, Regina; Andris, Cécile; Asgari, Nasrin; Barnett, Yael; Battistella, Roberto; Behbehani, Raed; Berger, Thomas; Bikbov, Mukharram M; Biotti, Damien; Biousse, Valerie (December 2022). "Diagnosis and classification of optic neuritis". The Lancet Neurology. 21 (12): 1120–1134. doi:10.1016/S1474-4422(22)00200-9. PMID 36179757. S2CID 252564095.
- Khurana, A K; Khurana, Aruj K; Khurana, Bhawna P (2019). Comprehensive Ophthalmology (7th ed.). New Delhi: Jaypee Brothers Medical Publishers. ISBN 978-93-5270-686-0.
- Marcovitch, Harvey, ed. (2018). Black's Medical Dictionary (43rd ed.). A&C Black – via Credo Reference.
- "Optic neuritis". Mayo Clinic.
- Lucchinetti, C. F.; L. Kiers; A. O'Duffy; M. R. Gomez; S. Cross; J. A. Leavitt; P. O'Brien; M. Rodriguez (November 1997). "Risk factors for developing multiple sclerosis after childhood optic neuritis". Neurology. 49 (5): 1413–1418. doi:10.1212/WNL.49.5.1413. PMID 9371931. S2CID 33205877.
- Lana-Peixoto, MA; Andrade, GC (June 2001). "The clinical profile of childhood optic neuritis". Arquivos de Neuro-Psiquiatria. 59 (2–B): 311–7. doi:10.1590/S0004-282X2001000300001. PMID 11460171.
- Rizzo JF, Lessell S (1991). "Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles". Arch. Ophthalmol. 109 (12): 1668–72. doi:10.1001/archopht.1991.01080120052024. PMID 1841572.
- Biousse, Valérie; Campion, Edward W.; Newman, Nancy J. (2015). "Ischemic Optic Neuropathies". New England Journal of Medicine. 372 (25): 2428–2436. doi:10.1056/NEJMra1413352. ISSN 0028-4793. PMID 26083207.
- Riordan-Eva, P. (1 January 2004). "Clinical assessment of optic nerve disorders". Eye. 18 (11): 1161–1168. doi:10.1038/sj.eye.6701575. PMID 15534601.
- Isobe N, Yonekawa T, Matsushita T, et al. Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica. Neurochem Res. 2013;38(5):997-1001. doi:10.1007/s11064-013-1009-0
- Nicolaie, MA; van Houwelingen, HC; Putter, H (December 2015). "Vertical modelling: Analysis of competing risks data with missing causes of failure". Statistical Methods in Medical Research. 24 (6): 891–908. doi:10.1177/0962280211432067. PMID 22179822. S2CID 43277083.
- Chalmoukou Konstantina; et al. (2015). "Recurrent Optic Neuritis (rON) is characterised by Anti-MOG Antibodies: A follow-up study". Neurology. 84 (14): 274.
- Kidd D.; Burton B.; Plant G. T.; Graham E. M. (2003). "Chronic relapsing inflammatory optic neuropathy (CRION)". Brain. 126 (2): 276–284. doi:10.1093/brain/awg045. PMID 12538397.
- Narayan et al. Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients, November 2018, MS and related disorders, Volume 28, February 2019, Pages 86-90, doi: https://doi.org/10.1016/j.msard.2018.11.026
- Petzold, Axel; Fraser, Clare L.; Abegg, Mathias; Alroughani, Raed; Alshowaeir, Daniah; Alvarenga, Regina; Andris, Cécile; Asgari, Nasrin; Barnett, Yael; Battistella, Roberto; Behbehani, Raed; Berger, Thomas; Bikbov, Mukharram M.; Biotti, Damien; Biousse, Valerie (2022-09-27). "Diagnosis and classification of optic neuritis". The Lancet Neurology. 21 (12): 1120–1134. doi:10.1016/S1474-4422(22)00200-9. ISSN 1474-4422. PMID 36179757. S2CID 252564095.
- Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH (1993). "The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group". N. Engl. J. Med. 329 (24): 1764–9. doi:10.1056/NEJM199312093292403. PMID 8232485.
- Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR (1992). "A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group". N. Engl. J. Med. 326 (9): 581–8. doi:10.1056/NEJM199202273260901. PMID 1734247.
- Gal RL, Vedula SS, Beck R (2015). "Corticosteroids for treating optic neuritis". Cochrane Database Syst Rev. 14 (8): CD001430. doi:10.1002/14651858.CD001430.pub4. PMC 4730547. PMID 26273799.
- Petzold A, Braithwaite T, Oosten BV, Balk L, Martinez-Lapiscina EH, Wheeler R, Wiegerinck N, Waters C, Plant GT (2019). "Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence". J Neurol Neurosurg Psychiatry. 91 (1): jnnp-2019-321653. doi:10.1136/jnnp-2019-321653. PMC 6952848. PMID 31740484.
- Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT (1995). "Optic neuritis: a population-based study in Olmsted County, Minnesota". Neurology. 45 (2): 244–50. doi:10.1212/WNL.45.2.244. PMID 7854520. S2CID 25800388.
- Petzold A (2013). "Optic Neuritis: Another Dickensian Diagnosis". Neuro-Ophthalmology. 37 (6): 247–250. doi:10.3109/01658107.2013.830313. PMC 5291069. PMID 28167994.